

CURRICULUM VITAE et STUDIORUM

Dott. Andrea Domenico Maria Manazza

E-mail:

Dati personali

Nato a Torino il 5 Dicembre 1973.

Titoli di studio

- Laurea in Medicina e Chirurgia presso l'Università degli Studi di Torino, conseguita nella sessione straordinaria dell'anno accademico 1997/98 con la votazione di 110/110, lode e dignità di stampa; tesi sperimentale discussa: "Studio dell'espressione del trascritto ibrido NPM-ALK nei linfomi pediatrici".
- Dottorato di Ricerca in Oncologia umana, presso l'Università degli Studi di Torino, conseguito il 1° febbraio 2005; tesi sperimentale difesa: "Applicazione della metodica di interferenza a RNA (RNAi) per lo studio della proteina oncogenica ALK in linfomi ALCL".
- Specializzazione in Oncologia, presso l'Università degli Studi di Torino, conseguita nella sessione ordinaria dell'anno accademico 2007/2008, con la votazione di 70/70; tesi discussa: "Utilizzo di Oxaliplatino, 5-FluoroUracile e acido folinico, come terapia di II linea in pazienti affetti da carcinoma avanzato del pancreas".
- "Máster en medicina paliativa y tratamiento de soporte del enfermo con cáncer", presso la Universidad Autónoma de Madrid, conseguito il 21 ottobre 2011. Dissertazione finale su "Impacto de la intervención de un equipo de Cuidados Paliativos en un área de montaña del Norte de Italia". (Riconosciuto con Postilla dell'Aja in data 07/11/2016, e con dichiarazione di valore *in loco* in data 17/03/2017).

Occupazione attuale

- Dirigente Medico presso SS Cure Palliative, ASL TO4, Chivasso.

Esperienza lavorativa precedente

- Dottorando (poi membro dell'equipe di ricerca) presso il laboratorio di Oncologia Molecolare, CeRMS, Molinette, 01/04/2000 – 25/1/2009.
- Libero Professionista, Medico Palliativista, presso la ASL TO4, dal 26/1/2009 al 30/04/2013 (20 ore settimanali, in media);

- Specialista Ambulatoriale, Medico Palliativista, a tempo determinato, presso la ASL TO4, dal 1/5/2013 al 28/2/2014;
- Libero Professionista, Palliativista (assistenza domiciliare e in hospice; 30 ore settimanali, in media), presso la Associazione Casainsieme ONLUS, dal 01/3/2014 al 31/3/2015;
- Libero Professionista, medico di guardia interdivisionale, presso il Presidio Sanitario Ospedale Cottolengo, dal 1/8/2009 al 31/01/2012 (36 ore mensili, in media);
- Libero Professionista, Oncologo, presso la ASL TO4, dal 28/10/2009 al 14/01/2011 (10 ore settimanali, in media);
- Libero Professionista, medico di guardia, presso la Piccola Casa della Divina Provvidenza, dal 01/02/2012 al 31/03/2015 (36 ore mensili, in media);
- Dirigente Medico di Cure Palliative, presso SC Cure Palliative, ASL CN1, Busca, dal 1/4/2015 al 9/9/2018.

Pubblicazioni e comunicazioni

Articoli *in extenso*

1. Marazzi F, Serra I, **Manazza A**, Marengo M, Tamagnone M, Pino C, Bottaro C, Falconi D, Gherzi M, Tattoli F, Formica M: “La sospensione della dialisi e le cure palliative: da un caso clinico una riflessione generale”. G. Ital. Nefrol. (2019) 36; Suppl.73:83-100.
2. Ceccon M, Merlo ME, Mologni L, Poggio T, Varesio LM, Menotti M, Bombelli S, Rigolio R, **Manazza AD**, Di Giacomo F, Ambrogio C, Giudici G, Casati C, Mastini C, Compagno M, Turner SD, Gambacorti-Passerini C, Chiarle R, Voena C: “Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency”. Oncog. 2015 Dec 14.
3. Morini S, Perrone G, Borzomati D, Vincenzi B, Rabitti C, Righi D, Castri F, **Manazza AD**, Santini D, Tonini G, Coppola R, Onetti Muda A: “Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival”. Pancreas. 2013 Jan;42(1):60-6.
4. Galfrascoli E, Piva S, Cinquini M, Rossi A, La Verde N, Bramati A, Moretti A, **Manazza A**, Damia G, Torri V, Muserra G, Farina G, Garassino MC; on behalf of ORION Collaborative Group: “Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis.”, Dig Liver Dis. 2011 Apr ;43(4): 286-294.
5. Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, **Manazza AD**, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G: “Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)”. Curr Cancer Drug Targets, (2010) Jan 1; 11(1):123-9.
6. Ambrogio C, Voena C, **Manazza AD**, Martinengo C, Costa C, Kirchhausen T, Hirsch H, Inghirami G, Chiarle R: “The Anaplastic Lymphoma Kinase controls cell shape and growth of Anaplastic Large Cell Lymphoma through Cdc42 activation”. Cancer Res, (2008) November 1; 68: 8899-8907.

7. Costa C*, Barberis L*, Ambrogio C, **Manazza AD**, Patrucco E, Azzolino O, Neilsen PO, Circolo E, Altruda F, Prestwich GD, Chiarle R, Wymann M, Ridley A, Hirsch E: "Negative feedback regulation of Rac in leukocytes from mice expressing a constitutively active phosphatidylinositol 3-kinase gamma". *Proc Natl Acad Sci USA*, (2007) September 4;104(36):14354-9.
8. Vanni C, Visco V, Mancini P, Parodi A, Ottaviano C, Ognibene M, **Manazza AD**, Retta SF, Varesio L, Torrisi MR, Eva S: "Inhibition of PI3K induces Rac activation and membrane ruffling in Proto-Dbl expressing cells". *Cell Cycle*, (2006) November 15; 22(5): 2657-65.
9. Schiffer D, **Manazza AD**, Tamagno I: "Nestin expression in neuroepithelial tumors". *Neurosci Lett*, (2006) May 29;400(1-2):80-5.
10. Terreno E, Geninatti C, Belfiore S, Biancone L, Cabella C, Esposito G, **Manazza AD**, Aime S: "Effect of the intracellular localization of a Gd-based imaging probe on the relaxation enhancement of water protons". *Magn Reson Med*, (2006) Mar;55(3):491-7.
11. Piva R*, Chiarle R*, **Manazza AD***, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G: "Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas". *Blood*, (2006) Jan 15;107(2):689-97.
12. Ambrogio C, Voena C, **Manazza AD**, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Erba EB, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R: "p130Cas mediates the transforming properties of the anaplastic lymphoma kinase". *Blood*, (2005) Dec 1;106(12):3907-16.
13. **Manazza AD**, Bonello L, Pagano M, Chiusa L, Novero D, Stacchini A, Martini G, Vitolo U, Tarella C, Inghirami G, Palestro G, Chiarle R: "Follicular origin of a subset of CD5+ diffuse large B-cell lymphomas". *Am J Clin Pathol*, (2005) Aug;124(2):182-90.
14. Papotti M, **Manazza AD**, Chiarle R, Bussolati G: "Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei". *Virchows Archiv*, (2004) 444:350-355.
15. Sandri S, **Manazza AD**, Bertin M, Silengo M, Basso ME, Forni M, Madon E: "Schinzel-Giedion syndrome with sacrococcygeal teratoma: a new patient with an uncommon survival". *J Ped Haematol Oncol*, (2003) 25:558-561.

Comunicazioni orali

16. III International interdisciplinary seminar, Ponte di Legno (BS), 27/12/1994-3/1/1995: "Brain death: technical and ethical problems in defining it."
17. 37th Congress of the Italian Society of Haematology, Turin, 26-29/9/1999: "TEL/AML-1 rearranged childhood ALL". *Publ. in Haematologica*, vol. 84, Suppl. to n° 9, September 1999.

18. VI International interdisciplinary seminar, Ponte di Legno (BS), 27/12/2001-02/01/2002: "Stem cells research: update and ethical issues".
19. 1st Italian RNA interference symposium, Milan, 8/6/2004: "Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human Anaplastic Large Cell Lymphoma cells".
20. XII Meeting European Association for Haematopathology, Saloniki, 26/9-1/10/2004: "NPM-ALK modifies cytoskeleton and cellular shape by the activation of Rac1, Cdc42 and p130 Cas".
21. XII Meeting European Association for Haematopathology, Saloniki, 26/9-1/10/2004: "CD30 expression in anaplastic large lymphomas is dependent on ALK tyrosine kinase activity via STAT3 phosphorylation and JunB upregulation".
22. 94th Annual Meeting United States and Canadian Academy of Pathology, San Antonio (TX), 26/2 – 4/3/2005: "Targeting oncogenic ALK by lentiviral small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells". Publ. in Laboratory Investigation vol. 85: 246A, 1141, Suppl. 1 Jan 2005.
23. Congress of the Italian Society of Immunology, clinical immunology and allergology, Brescia, June 2005: "Constitutive in vivo delocalization of PI3Kgamma selectively blocks chemotaxis by altering PIP3 polarization".
24. 60th Harden Conference - Inositol Phosphates and Lipids - Regulation and Functions. St Martin's College, Ambleside, Lake District, UK, 13-18/8/2005: "Constitutive delocalization of PI3K□ selectively blocks chemotaxis by altering PtdIns(3,4,5)-P₃ polarization".
25. XXXVI Congress of the Italian Society of Neurology, Cernobbio (Como-Italy), 8-12/10/2005: "The origin of gliomas in the frame of neural stem cell concept".
26. Focus sulle Biotecnologie, Milan, 14-16/12/2005: "Impiego della tecnica dell'interferenza a RNA in oncologia per la validazione di bersagli terapeutici e per la caratterizzazione di profili di espressione genica".
27. Keystone Symposium: Jaks, Stats and Immunity, 5–10/1/2007, Steamboat Springs, Colorado, USA: "Dissection of critical pathways instrumental to the Anaplastic Lymphoma Kinase oncogenic activity".
28. 2007 CNIO Cancer Conference, Madrid, 19-21/2/2007: "NPM-ALK regulates lymphoma cell growth and morphology through the Rho family GTPases".
29. ABCD and UK Adhesion Meeting, Rome, 30-31/3/2007: "The tyrosine kinase NPM-ALK regulates lymphoma cell growth and morphology through the Rho family GTPases".
30. ABCD and UK Adhesion Meeting, Rome, 30-31/3/2007: "Constitutive elevation of phosphoinositide 3-Kinase gamma activity in mice does not increase tumor susceptibility, but reveals a negative feedback loop regulating Rac during leukocyte chemotaxis".

31. XIV Meeting of the EAHP/SH in Bordeaux, France, 20-25/9/2008: “ Loss of T cell identity and by-pass of TCR signalling by oncogenic tyrosine kinase activity in anaplastic large cell lymphoma”. J Hematopathol (2008) 1:161–256.
32. XI International interdisciplinary seminar, Madrid (Spain), 01-06/01/2009: “Detecting consciousness and free will in a patient in persistent vegetative state”.
33. XII International interdisciplinary seminar, Barcelona (Spain), 01-06/01/2010: “Charles Darwin and evolution”.
34. Seminario Le Cure Palliative e la Neurologia, Colletterto Giacosa, (Torino) 7/5/2011: “Il dolore cronico e il dolore incidente nei pazienti neuro-oncologici o affetti da SLA: un vecchio problema con nuove proposte terapeutiche.”
35. Seminario Problemi Medico-legali in cure palliative e terapia del dolore, Ivrea, 19/11/2011: “La Unità Organizzativa di Cure Palliative di Ivrea e Cuorgnè (ASL TO4): risultati ottenuti e problemi aperti”.
36. Seminario Internazionale di Cure Palliative domiciliari 2012, Ivrea, 21/1/2012: “La complessità della comunicazione in un’equipe di cure palliative domiciliari: l’esperienza di Ivrea e Cuorgnè”.
37. XIX Congresso della Società Italiana di Cure Palliative, Torino, 9-12/10/2012: “La “congiura del silenzio” tra i pazienti afferenti ad un servizio di Cure Palliative”.
38. Foro de Atención Primaria y atención domiciliaria, Chía, Colombia, 16/7/2013: “Experiencias de atención domiciliaria en pacientes paliativos en Italia”.

Comunicazioni tipo poster

39. XXXVI AIEOP national congress, Brescia, 31/5-1/6 –1999: “Preliminary data on molecular follow-up of NPM-ALK in paediatric ALCL, via t(2;5)”. Riv. It. Ped., vol. 25, Suppl. to n° 3, june 1999.
40. XI Meeting European Association for Haematopathology, Siena, 26-30/05/2002: XI Meeting European Association for Haematopathology, Siena, 26-30/05/2002: “De novo CD5+ aggressive B-cell lymphoma: pathologic study of 29 cases and identification of a new follicular variant”, J Clin Pathol, (2002), vol 55, suppl, A13.
41. 2004 CNIO Symposium, Madrid, 3-6/2/2004: “Targeting oncogenic ALK by stable small interfering RNA induces cell death of human Anaplastic Large Cell Lymphoma cells”.
42. 4th FEBS Dubrovnik signaling conference, “Targeting oncogenic ALK by small interfering RNA induces growth arrest and apoptosis of human anaplastic large cell lymphoma cells”.
43. 21st ESMRMB meeting, Copenhagen, 9-12/9/2004: “Relaxation efficiency of cell internalised Gd-HPDO3A”.

44. Gordon Research Conference on “Chemotactic cytokines”, Aussois, France, 19-24/09/04: “Constitutive delocalization of PI3Kgamma in vivo selectively blocks chemotaxis by altering chemokine/chemoattractant-driven PIP3 polarization”.
45. ABCD Congress. Signal transduction mechanisms in cell adhesion and differentiation processes, Pontignano, Italy, March 2005: “La localizzazione del PIP3 prodotto da PI3Kgamma regola specifiche funzioni leucocitarie”.
46. 3rd Italian siRNA Symposium: Applications in oncogenetics, Turin, 07/6/2005: “Identification of genomic and proteomic signatures in lymphomas by inducible shRNA”.
47. FEBS Lecture Course Lipid-protein interaction in signalling and membrane traffic. Santa Maria Imbaro (Ch), Italy, 10-15/6/2005: “Constitutive delocalization of PI3Kgamma in vivo selectively blocks chemotaxis by altering chemokine/chemoattractant-driven PIP3 polarization”.
48. RNAi Europe 2005, Amsterdam, 28-29/9/2005: “Identification of genomic and proteomic signatures in lymphomas by inducible shRNA”.
49. Gene Silencing International Workshop, Turin, Italy, 11/11/2005: “Validation of therapeutic targets and identification of genomic signatures in lymphomas by inducible shRNA”.
50. 97th AACR Conference, Los Angeles, 14-18/4/2007: “Dissection of critical pathways instrumental for Anaplastic Lymphoma Kinase transformation”.
51. ECCO 14th Conference, Barcelona, 23-27/09/2007: “Chemotherapy with gemcitabine as first-line treatment for advanced biliary tract carcinoma”, *Ann. Oncol.*, 2007; Vol. 18, Suppl. 11, x16.
52. *Nature*-CNIO Conference, Madrid, 3-6/10/2007: “Loss of T cell identity and by-pass of TCR signalling by oncogenic tyrosine kinase activity”.
53. AISP 32nd National Congress, Montecatini Terme (PT), Italy, 2-4/10/2008: “Diagnostic Role of [18F]-FDG-PET/CT in the Preoperative Evaluation of Pancreatic Lesions”, *J Pancreas (Online)* 2008; 9 (6 Suppl):772-870.
54. Joint ECCO 15th /ESMO 34th Multidisciplinary Congress, Berlin, 20-24/09/2009: “Bevacizumab related adverse events in patients affected by metastatic colorectal cancer: a meta-analysis”, *European Journal of Cancer*, 2009; Suppl., vol. 7, n.2, p343.
55. XVI Congresso della Società Italiana di Cure Palliative, Lecce, 27-30/10/2009: “La rete locale di Cure Palliative presso la sede di Chivasso (TO) dell’ASL TO4”.
56. 21st Meeting of the European Association for Cancer Research, Oslo, 26-29/6/2010: “Trapping and silencing of NPM-ALK in the nucleus is a fundamental event for NPM-ALK mediated cell transformation.” *Eur J Cancer, Suppl.*, vol. 8: 383, 2010.
57. 15th Meeting of the European Association for Haematopathology, Uppsala, Sweden, 25-30/9/2010: “Trapping and silencing of NPM-ALK in the nucleus is a fundamental event for NPM-ALK mediated cell transformation”.

58. XVIII Congresso della Società Italiana di Cure Palliative, Trieste, 26-29/10/2011: “La Cure Palliative in Neurologia: l’esperienza di Ivrea”.
59. XIII World Congress of the European Association for Palliative Care, Prague, Czech Republic, 30/5-2/6/2013: “Hyperalgesia and Propofol Terminal Sedation in a Patient with Neuropathic Cancer Pain”.
60. 2013 ENCALS Meeting, Sheffield, UK, 31/5-2/6/2103: “Palliative care in Amyotrophic Lateral Sclerosis: a population based study in Italy”.
61. XLIV Meeting of the Italian Society of Neurology, Milan, Italy, 2-5/11/2013: “Advance directives and palliative care in amyotrophic lateral sclerosis: an epidemiological study”.
62. 24th International symposium on ALS/MND, Milan, Italy, 6-8/12/2013: “Palliative care in Amyotrophic Lateral Sclerosis: a population-based study in Italy”. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Nov;14 Suppl 2:64-83.
63. XXI Congresso della Società Italiana di Cure Palliative, Arezzo, 9-12/10/2014: “Revisione sistematica della attività clinico-assistenziale in una nuova UOCP.”
64. 4th International Seminar of the European Palliative Care Research Centre, Amsterdam, The Netherlands, 15/17/10/2014: “Sistematic review of the clinical activity of a new palliative care unit”.
65. 2015 AACR Annual Meeting, Philadelphia. 18-22/4/2015: “Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency”.
66. 58° Congresso, Società Italiana di Nefrologia, Rimini, 4-8/10/2017: “La responsabilità della scelta di sospendere la dialisi. Casi di complessità irriducibile e riflessioni sull’autonomia del medico”.
67. 59° Congresso, Società Italiana di Nefrologia, Rimini, 3-6/10/2018: “Progetto di un percorso clinico condiviso con il paziente affetto da insufficienza renale cronica (IRC), per realizzare lo spirito della legge 219/2017, <<Norme in materia di consenso informato e di disposizioni anticipate di trattamento>>, pur in assenza di decreti attuativi.”